The right tools to monitor the cytokine storm
Whether in infectious diseases (COVID-19, Sepsis, Zika), immuno-oncology, auto-immune, inflammatory disorders, evaluating innovative immunotherapies (ICPI) or cell therapies (CAR-T cells), uncontrolled release of cytokines, known as cytokine storm, may be life-threatening for patients. Detecting harmful levels of cytokines is a matter of life or death for patients, and crucial for adapting patient care.
As an expert in soluble biomarker analysis, ABL is a partner of choice to support you overcome these challenges.
Need multiplexed assays on low volume samples? Not a problem!
Discover the Ella system:
- Fully automated fluidic immunoassay platform
- Validated standard curve included within the cartridge
- Multi-analytes possible with NO multiplexing: up to 8 analytes can be analyzed seperately limitating antibody cross-reactivity
- Sub-picogram level sensitivity, 4+ logs of dynamic range and high reproducibility
- Very low sample volume: 2.5 to 25 µL per duplicate and triplicate
- Customizable cartridges for building your own assays
- High throughput : up to ~300 samples a day
- Extended catalogue: 190+ soluble mediators available
(Ultra)Sensitive & Reliable assays with MSD QuickPlex SQ120
Case Study - ELISPOT on the SPOT!
Understanding how an investigational product modulates the immune system is of outstanding value in many therapeutic areas and indications. The enzyme-linked
immunosorbent spot (ELISpot) assay was firstly developed more than 30 years ago for the detection of antibody-secreting cells1,2. Since then, this method has become one of the most popular for documenting functionality of antigen-specific T cell responses in the context of therapies expected to modulate the immune system, such as preventive or therapeutic, universal or individualized vaccines, but also therapeutic antibodies, immune check-point inhibitors or oncolytic viral therapies, in many fields, including immuno-oncology, infectious diseases, autoimmunity, (neuro)inflammation or allergy.
If there are indisputable advantages (sensitivity, measure of cell function, low-cost assay) of the ELISpot assay for evaluating cell-mediated immunogenicity in large-scale
clinical trials, many factors, if not under control, may affect assay performance and outcomes.